Beryl Drugs Ltd — Updates, 12-04-2025: Company Update

Beryl Drugs Limited has filed its Reconciliation of Share Capital Audit Report for the quarter ending March 31, 2025, as part of its compliance with SEBI regulations. The report confirms that there were no share transfers during the specified period, and all share certificates were issued within the required timeframe for any changes. This update reflects the company's adherence to regulatory requirements, potentially fostering investor confidence in its operational compliance. While there are no immediate impacts on financial performance noted, maintaining compliance positions the company well for future stability, which might signal a positive outlook to investors.